Table 1 Overall observed 3-, 5- and 10-year survival rates of TCs for both genders in relation to the 4 age cohorts (<20 years, 20–44 years, 45–69 years and >69 years of age) and the 4 histological types (papillary, follicular, medullary and anaplastic carcinomas); n = 310 cases; period 1990–1999.
From: Thyroid cancer in Luxembourg: a national population-based data report (1983–1999)
1990–1994 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Papillary carcinomas | Follicular carcinomas | Medullary carcinomas | Anaplastic carcinomas | |||||||||
3 y | 5 y | 10 y | 3 y | 5 y | 10 y | 3 y | 5 y | 10 y | 3 y | 5 y | 10 y | |
<20 years | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) |
20–44 y. | 100% (42/42) | 100% (42/42) | 97.6%* (41/42) | 100% (9/9) | 100% (9/9) | 88.9%* (8/9) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) | (0/0) |
45–69 y. | 91.8%* (45/49) | 89.8%* (44/49) | 87.8%* (43/49) | 90.9%* (10/11) | 90.9%* (10/11) | 81.8%* (9/11) | 66.7%* (2/3) | 66.7%* (2/3) | 66.7%* (2/3) | (0/0) | (0/0) | (0/0) |
>69 years | 66.7%* (2/3) | 33.3%* (1/3) | 0% (0/3) | 57.1%* (4/7) | 42.9%* (3/7) | 42.9%* (3/7) | 100% (1/1) | 100% 1/1) | 100% (1/1) | 0% (0/1) | 0% (0/1) | 0% (0/1) |
1995–1999 | ||||||||||||
Papillary carcinomas | Follicular carcinomas | medullary carcinomas | Anaplastic carcinomas | |||||||||
3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | |
<20 years | 100% (3/3) | 100% (3/3) | - | (0/0) | (0/0) | - | (0/0) | (0/0) | - | (0/0) | (0/0) | - |
20–44 y. | 100% (65/65) | 100% (65/65) | - | 100% (7/7) | 100% (7/7) | - | 100% (3/3) | 100% (3/3) | - | (0/0) | (0/0) | - |
45–69 y. | 98.7%* (76/77) | 98.7%* (76/77) | - | 100% (9/9) | 100% (9/9) | - | 100% (4/4) | 100% (4/4) | - | 0% (0/2) | 0% (0/2) | - |
>69 years | 88.9%* (8/9) | 77.8%* (7/9) | - | 50%* (1/2) | 50%* (1/2) | - | (0/0) | (0/0) | - | 0% (0/3) | 0% (0/3) | - |
1990–1999 | ||||||||||||
Papillary carcinomas | Follicular carcinomas | medullary carcinomas | Anaplastic carcinomas | |||||||||
3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | 3 y | 5 y | 10 y** | |
<20 years | 100% (3/3) | 100% (3/3) | - | (0/0) | (0/0) | - | (0/0) | (0/0) | - | (0/0) | (0/0) | - |
20–44 y. | 100% (107/107) | 100% (107/107) | - | 100% (16/16) | 100% (16/16) | - | 100% (3/3) | 100% (3/3) | - | (0/0) | (0/0) | - |
45–69 y. | 96.0%* (121/126) | 95.2%* (120/126) | - | 95.0%* (19/20) | 95%* (19/20) | - | 85.7%* (6/7) | 85.7%* (6/7) | - | 0% (0/2) | 0% (0/2) | - |
>69 years | 83.3%* (10/12) | 66.7%* (8/12) | - | 55.6%* (5/9) | 44.4%* (4/9) | - | 100% (1/1) | 100% (1/1) | - | 0% (0/4) | 0% (0/4) | - |